Attached files
| file | filename |
|---|---|
| EX-10.15 - EXHIBIT 10.15 - Cyclacel Pharmaceuticals, Inc. | t1700098_ex10-15.htm |
| EX-32.2 - EXHIBIT 32.2 - Cyclacel Pharmaceuticals, Inc. | t1700098_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Cyclacel Pharmaceuticals, Inc. | t1700098_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Cyclacel Pharmaceuticals, Inc. | t1700098_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Cyclacel Pharmaceuticals, Inc. | t1700098_ex31-1.htm |
| EX-10.14 - EXHIBIT 10.14 - Cyclacel Pharmaceuticals, Inc. | t1700098_ex10-14.htm |
| 10-K - FORM 10-K - Cyclacel Pharmaceuticals, Inc. | t1700098-10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Nos. 333-205153, 333-183483, and 333-143786) on Form S-8 and (Nos. 333-211046 and 333-187801) on Form S-3 of Cyclacel Pharmaceuticals, Inc. of our report dated March 31, 2017, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2016.
/s/ RSM US LLP
New York, New York
March 31, 2017
March 31, 2017